These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 18065924)

  • 61. Comparison between gadolinium and iodine contrast for percutaneous intervention in atherosclerotic renal artery stenosis: clinical outcomes.
    Kane GC; Stanson AW; Kalnicka D; Rosenthal DW; Lee CU; Textor SC; Garovic VD
    Nephrol Dial Transplant; 2008 Apr; 23(4):1233-40. PubMed ID: 18256017
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Anaphylactic shock induced by intravenous gadopentetate dimeglumine.
    Tardy B; Guy C; Barral G; Page Y; Ollagnier M; Bertrand JC
    Lancet; 1992 Feb; 339(8791):494. PubMed ID: 1346846
    [No Abstract]   [Full Text] [Related]  

  • 63. Safety of intravenous gadolinium (Gd-BOPTA) infusion in patients with renal insufficiency.
    Townsend RR; Cohen DL; Katholi R; Swan SK; Davies BE; Bensel K; Lambrecht L; Parker J
    Am J Kidney Dis; 2000 Dec; 36(6):1207-12. PubMed ID: 11096046
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Renal tolerance of gadolinium-DTPA/dimeglumine in patients with chronic renal failure.
    Haustein J; Niendorf HP; Krestin G; Louton T; Schuhmann-Giampieri G; Clauss W; Junge W
    Invest Radiol; 1992 Feb; 27(2):153-6. PubMed ID: 1601607
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Influence of excess ligand on Nephrogenic Systemic Fibrosis associated with nonionic, linear gadolinium-based contrast agents.
    Semelka RC; Prybylski JP; Ramalho M
    Magn Reson Imaging; 2019 May; 58():174-178. PubMed ID: 30471330
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Clinical Safety of Gadoteridol, Representative of the Macrocyclic Class of Gadolinium-Based Contrast Agents.
    Runge VM
    J Magn Reson Imaging; 2020 Mar; 51(3):869-870. PubMed ID: 31614049
    [No Abstract]   [Full Text] [Related]  

  • 67. [Nephrogenic systemic fibrosis].
    Samtleben W
    Radiologe; 2007 Sep; 47(9):778-84. PubMed ID: 17717643
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Safety and efficacy of dotarem (Gd-DOTA) versus magnevist (Gd-DTPA) in magnetic resonance imaging of the central nervous system.
    Oudkerk M; Sijens PE; Van Beek EJ; Kuijpers TJ
    Invest Radiol; 1995 Feb; 30(2):75-8. PubMed ID: 7782190
    [TBL] [Abstract][Full Text] [Related]  

  • 69. An Investigation of Transient Severe Motion Related to Gadoxetic Acid-enhanced MR Imaging.
    Motosugi U; Bannas P; Bookwalter CA; Sano K; Reeder SB
    Radiology; 2016 Apr; 279(1):93-102. PubMed ID: 26473642
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [What are the remaining indications for gadolinium contrast in CT].
    Clément O
    J Radiol; 2009 Mar; 90(3 Pt 1):261. PubMed ID: 19421108
    [No Abstract]   [Full Text] [Related]  

  • 71. Editorial for "Gadolinium Clearance in the First 5 Weeks After Repeated Intravenous Administration of Gadoteridol, Gadoterate Meglumine and Gadobutrol to rats".
    Liang X; Yeh CH
    J Magn Reson Imaging; 2021 Nov; 54(5):1645-1646. PubMed ID: 34046961
    [No Abstract]   [Full Text] [Related]  

  • 72. Acute renal failure after arteriography with a gadolinium-based contrast agent.
    Gemery J; Idelson B; Reid S; Yucel EK; Pagan-Marin H; Ali S; Casserly L
    AJR Am J Roentgenol; 1998 Nov; 171(5):1277-8. PubMed ID: 9798860
    [No Abstract]   [Full Text] [Related]  

  • 73. Observational study on the safety profile of gadoterate meglumine in 35,499 patients: The SECURE study.
    Soyer P; Dohan A; Patkar D; Gottschalk A
    J Magn Reson Imaging; 2017 Apr; 45(4):988-997. PubMed ID: 27726239
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Safety of gadobutrol, a new generation of contrast agents: experience from clinical trials and postmarketing surveillance.
    Voth M; Rosenberg M; Breuer J
    Invest Radiol; 2011 Nov; 46(11):663-71. PubMed ID: 21623211
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Assessment of utilization and pharmacovigilance based on spontaneous adverse event reporting of gadopentetate dimeglumine as a magnetic resonance contrast agent after 45 million administrations and 15 years of clinical use.
    Knopp MV; Balzer T; Esser M; Kashanian FK; Paul P; Niendorf HP
    Invest Radiol; 2006 Jun; 41(6):491-9. PubMed ID: 16763467
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Nephrogenic systemic fibrosis: possible association with a predisposing infection.
    Golding LP; Provenzale JM
    AJR Am J Roentgenol; 2008 Apr; 190(4):1069-75. PubMed ID: 18356457
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Magnetic resonance imaging contrast agents.
    Runge VM
    Curr Opin Radiol; 1992 Feb; 4(1):3-12. PubMed ID: 1739599
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Nephrogenic systemic fibrosis: experimental studies confound prevailing theory of free gadolinium as a causative factor.
    Jakobsen J
    Acta Radiol; 2008 Jul; 49(6):616-7. PubMed ID: 18568551
    [No Abstract]   [Full Text] [Related]  

  • 79. Gadopentetate dimeglumine: observations on the clinical research process.
    Kieffer SA
    Radiology; 1990 Jan; 174(1):7-8. PubMed ID: 2403685
    [No Abstract]   [Full Text] [Related]  

  • 80. [Gadolinium-DTPA dimeglumine administered orally for the study of the abdomen with magnetic resonance. Clinical evaluation and tolerance].
    Squillaci E; Crecco M; Cecconi L; Lupoi D; Sergiacomi GL; Simonetti G
    Radiol Med; 1993 Sep; 86(3):284-93. PubMed ID: 8210538
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.